Nurix Therapeutics (NRIX) investor relations material

Advantages of degrader approach in immunology

• Degraders eliminate the entire target protein, removing both enzymatic and scaffolding functions, which inhibitors cannot fully address.

• Scaffolding functions of kinases like BTK and IRAK4 are clinically relevant and can drive disease even when enzymatic activity is blocked.

• Degraders can target proteins without active sites, such as transcription factors like STAT6, expanding druggable targets.

• Head-to-head cell-based assays show deeper responses with degraders compared to inhibitors.

• Degrader technology enables targeting of previously undruggable proteins, offering new therapeutic opportunities.

STAT6 degrader (NX-3911) program and partnership

• NX-3911 is partnered with Sanofi, which is leading IND-enabling studies, expected to complete this year.

• Nurix retains an option for 50/50 co-development and co-commercialization in the US after proof-of-concept studies.

• NX-3911 shows high selectivity for STAT6, with no degradation of other STAT family members at relevant concentrations.

• Rapid and complete STAT6 degradation demonstrated in cells and animal models, with oral dosing efficacy.

• The program targets a large market, with potential advantages over injectables like dupilumab due to oral administration and broad applicability.

BTK degrader (bexobrutideg) development

• Bexobrutideg is being developed for both oncology and immunology, with initial proof-of-concept in autoimmune hemolytic anemia.

• Tablet formulation is in healthy volunteer studies, aiming for improved dosing flexibility and convenience for immunology indications.

• Phase 1 data from healthy volunteers is expected this year, supporting future patient studies.

• Extensive prior patient data in oncology supports the molecule's development in immunology.